Del 153 i serien Handbook of Experimental Pharmacology

Stereochemical Aspects of Drug Action and Disposition

Häftad, Engelska, 2012

AvMichel F. Eichelbaum,Bernard Testa,Andrew Somogyi

729 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

This book aims to guide and inspire drug researchers as they enter the 21st century. Stereochemistry is an essential dimension in pharmacology and should be understood as such by all drug researchers whatever their background. When used as probes or as medicines, stereoisomeric drugs offer invaluable pharmacological insights or innovative therapeutic strategies.

Produktinformation

Utgivningsdatum2012-10-21
Mått155 x 235 x 26 mm
Vikt709 g
FormatHäftad
SpråkEngelska
SerieHandbook of Experimental Pharmacology
Antal sidor442
FörlagSpringer-Verlag Berlin and Heidelberg GmbH & Co. KG
ISBN9783642625756

Tillhör följande kategorier

Chemical Aspects.- 1 Recent Developments in Asymmetric Organic Synthesis: Principles and Examples.- 2 Stereoselective Separations: Recent Advances in Capillary Electrophoresis and High-Performance Liquid Chromatography.- 3 Stereochemical Issues in Bioactive Natural Products.- 4 Drug Racemization and Its Significance in Pharmaceutical Research.- 5 Physical Properties and Crystal Structures of Chiral Drugs.- Experimental Pharmacology.- 6 Chiral Recognition in Biochemical Pharmacology: An Overview.- 7 Enantioselectivity in Drug-Receptor Interactions.- 8 Mechanisms of Stereoselective Binding to Functional Proteins.- 9 Stereoselective Drug-Channel Interactions.- 10 Stereoselective Bioactivation and Bioinactivation — Toxicological Aspects.- Drug Absorption, Distribution, Metabolism, Elimination.- 11 Intestinal Drug Transport: Stereochemical Aspects.- 12 Enantioselective Plasma and Tissue Binding.- 13 Stereoselective Drug Metabolism and Drug Interactions.- 14 Metabolic Chiral Inversion of 2-Arylpropionic Acids.- 15 Stereoselective Renal Elimination.- Implications for Drug Development and Therapy.- 16 Regulatory Requirements for the Development of Chirally Active Drugs.- 17 Improving Clinical Risk/Benefit Through Stereochemistry.